• PLAC1 Targeting in Clear Cell Renal Cell Carcinoma

  2026-08-29

  A 2025 study identifies PLAC1 as an overexpressed, prognostically unfavorable factor in clear cell renal cell carcinoma and combines patient-data analysis, molecular validation, gene knockdown, and high-throughput virtual screening. The findings nominate Amaronol B and canagliflozin as experimental compounds that reduce PLAC1-associated ccRCC progression, while also defining important questions about target specificity and clinical translation.

• SB-3CT and MMP9: Translating ECM Control

  2026-08-28

  A translational analysis of SB-3CT as a selective gelatinase inhibitor for testing MMP-2 and MMP-9 biology across perineuronal-net, tumor metastasis, and cerebral ischemia models, with practical guidance on assay design, evidence boundaries, and research strategy.

• Bestatin-Derived Inhibitors of IRAP and ERAP1

  2026-08-28

  This study develops a stereoselective route to α-hydroxy-β-amino acid derivatives of bestatin and applies it to selective inhibition of oxytocinase-family M1 aminopeptidases. Structural analysis, biochemical testing, and cell-based evaluation identify a low-nanomolar IRAP inhibitor and implicate GAMEN-loop interactions as an important source of potency and selectivity.

• HOBt for Peptide and Amide Bond Synthesis

  2026-08-27

  HOBt supports high-fidelity amide bond formation when stereochemical control and mild reaction conditions matter. This workflow-focused guide connects its use in peptide synthesis with the EDC-mediated construction of indazole glucagon receptor antagonists, including practical optimization and troubleshooting strategies.

• Novel Ziprasidone Impurity: Structure and Significance

  2026-08-27

  The reference study identified and structurally characterized a previously unreported methylene ziprasidone dimer that appeared during scale-up of ziprasidone hydrochloride manufacture. By combining preparative HPLC with high-resolution mass spectrometry and multidimensional NMR, the authors established the impurity structure and proposed a plausible formation pathway, providing a practical framework for pharmaceutical impurity control.

• MTT Assay Workflow for Kidney Fibrosis Research

  2026-08-26

  Use MTT to distinguish treatment-related cytotoxicity from metabolic remodeling in renal tubular cell models. This practical workflow connects epirubicin–B56δ research with reproducible colorimetric viability testing, including setup, controls, optimization, and troubleshooting.

• FXR–KLF11 Signaling in Contrast AKI

  2026-08-26

  The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Its combination of mouse modeling, HK-2 cell experiments, transcriptomics, promoter assays, and genetic perturbation provides a mechanistic framework for evaluating CDCA in renal injury research.

• Nanoparticle Uptake Pathways in Human Corneal Cells

  2026-08-25

  Azadi and David examined how nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells using engineered PLGA nanoparticles and a mucosal in vitro model. The study linked particle properties to pathway-level behavior, identifying energy-dependent uptake dominated by macropinocytosis and caveolae-mediated endocytosis rather than phagocytosis.

• Septin4, VHL, and HIF-1α in Cardiomyocyte Apoptosis

  2026-08-25

  The 2021 Cell Death Discovery study identifies HIF-1α as a Septin4-interacting protein and shows that Septin4 promotes VHL-dependent HIF-1α degradation during hypoxic cardiomyocyte injury. These findings place Septin4 upstream of a key oxygen-adaptation pathway and suggest a mechanistic explanation for its proapoptotic activity in myocardial hypoxia.

• Temozolomide in DNA Repair and Glioma Research

  2026-08-24

  Temozolomide provides a controlled methylation-based DNA damage model for glioma, cancer biology, and chemotherapy resistance studies. This guide translates its chemistry into practical dosing, combination, readout, and troubleshooting workflows, including ATRX-informed assays inspired by recent high-grade glioma research.

• Tetraethylammonium chloride in Cell Assays

  2026-08-24

  This scenario-based guide explains how Tetraethylammonium chloride, SKU B7262, can strengthen mechanistic interpretation in cell viability, proliferation, cytotoxicity, and potassium-channel studies. It connects assay design, solution handling, data interpretation, and vendor qualification to documented chemical and quality-control information.

• ARCA Cy5 EGFP mRNA: Assay Architecture

  2026-08-23

  ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to separate cellular delivery from protein expression in a single reporter system. This guide presents an assay-design framework for interpreting Cy5, EGFP, trafficking, translation, and immune-response data in mammalian cells.

• E-64d at the Proteostasis Decision Point

  2026-08-22

  E-64d is a membrane-permeable cysteine protease inhibitor that helps separate calpain- and cathepsin-dependent phenotypes from autophagic or proteasomal degradation. This article translates a recent Arabidopsis autophagy study into practical assay decisions without treating E-64d as a nonspecific substitute for genetic pathway analysis.

• Betaine Hydrochloride for Translational Assays

  2026-08-22

  Betaine hydrochloride can be used as a deliberately controlled variable in enzyme, protease, cell culture, and molecular biology workflows—not merely as a soluble reagent. This guide connects practical assay design with the inflammation-focused esophageal cancer study of oridonin while clearly separating published findings from recommended validation experiments.

• BOP Reagent in Translational Prodrug Design

  2026-08-21

  A mechanistic and strategic guide to using BOP reagent in peptide and prodrug workflows, with a clear evidence bridge to carrier-free, ROS-responsive triterpene systems investigated for oral squamous cell carcinoma.

7957 records 8/531 page Previous Next First page 上5页 678910 下5页 Last page